Tender offer extended to Dec!

The depositary of the exchange offer has advised that, as of 9:00 a.m., New York City time, on August 15, 2014, a total of approximately 12,509,606 shares of Allergan common stock were validly tendered and not properly withdrawn in the exchange offer.




OH! Big turn out for the tender offer! You kidding me????????????????????

NO one wants shitty VRX stock! Joke! Hang it up VRX!

 

Yes! Huge turnout of responses for people to tender their shares of AGN stock! 15 million shares and that is all!!! That's pathetic. Deal is over people!

 

How long will this keep going on? Anyone have a clue?

 

the shareholders have spoken. they want to vote. Mr Pyott should allow that to happen and end this saga

 

Pyott is obviously afraid that Valeant will prevail if the shareholders have their say.

 

Only 4% accepted the tender offer. Yes, the shareholders have spoken and they have rejected
Valeant!

 

Valeant/Pershing have filed a lawsuit regarding the special meeting. The want it “as soon as reasonably possible” and to be scheduled prior to Allergan executing on any “alternative transaction”.

According to Barron's:
Valeant’s hostile attempt to acquire Allergan continues to progress, with Allergan announcing on Friday that the company received written requests from Pershing Square to call a Special Meeting. According to Pershing Square and Valeant, 31% of Allergan’s outstanding share ownership supports the request for a Special Meeting. Valeant ’s concomitant request for declaratory judgment from the Delaware Court which contains, amongst other things, a request for the Court to compel Allergan to hold the Special Meeting “as soon as reasonably possible” while unsurprising, given the resistance of Allergan’s Board to a combination between the two companies, seems premature, given that the Board has not yet responded to the request for a Special Meeting. Interestingly, Valeant’s request in the declaratory judgment for a Special Meeting to be scheduled prior to Allergan executing on any “alternative transaction”, while also premature in our view, supports our stance that use of Allergan’s balance sheet for a strategic acquisition likely constitutes the most feasible means of preventing a Valeant /Allergan combination from taking place.